Chromogranin A, LC/MS/MS

Message
For Specimen Integrity during Extreme Weather see the “Lockbox Usage in Extreme Weather” document at the top of this page.


Test Code
CHROMA


CPT Codes
86316

Preferred Specimen
1 mL serum collected in a red-top tube (no gel)


Minimum Volume
0.5 mL


Instructions
Collect blood in a standard red-top serum vacutainer tube. Allow blood to clot at room temperature. Centrifuge and separate the serum from the cells immediately. Do not store refrigerated. (Sample must not reach refrigerator temperature)


Transport Temperature
Frozen


Specimen Stability
Room temperature: 7 days
Refrigerated: Unacceptable
frozen: 31 days


Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Unspun red-top (no gel) tubes • Serum separator tube (SST)


Methodology
Chromatography/Mass Spectrometry

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule
Sets up 6 days a week.


Report Available
Reports in 3 to 5 days.


Reference Range
Adults <311 ng/mL


Clinical Significance
Chromogranin-A (CgA) is an acidic glycoprotein expressed in the secretory granules of most normal and neoplastic neuroendocrine (NE) cell types, where it is released together with peptide hormones and biogenic amines. Neuroendocrine tumors (NETs) are a form of cancer that differ from other neoplasia in that they synthesize, store, and secrete peptides, e.g., CgA and amines. CgA is secreted from neuroendocrine-derived tumors including foregut, midgut and hindgut gastrointestinal NETs, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas, some pituitary tumors, functioning and non-functioning pancreatic NETs.
Significantly elevated CgA levels have been found in patients with other diseases, such as impaired renal function, untreated benign essential hypertension, gastritis, prostatic carcinoma, and hyperparathyroidism. The best-characterized circulating biomarker that identifies NETs in general is CgA. Monitoring blood CgA levels may effectively provide information that is helpful in delineating tumor burden and rate of tumor growth, predicting tumor response to therapy and providing some indication as to prognosis.


Performing Laboratory
Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042


Last Updated: November 29, 2021


The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.